London, England, 4 February 2014 - The International Tennis Federation announced today that Manel Pérez Esteve has been found to have committed an Anti-Doping Rule Violation under Article 2.1 of the Tennis Anti-Doping Programme (presence of a Prohibited Substance in a player’s sample).
Mr Pérez Esteve, a 19-year-old tennis player from Spain, provided a sample on 14 October 2013 at the F35 Futures event held in El Prat, Spain. That sample was sent to the WADA-accredited laboratory in Montreal, Canada for analysis, and was found to contain terbutaline, a beta-2 agonist. Terbutaline is a Prohibited Substance under the 2013 WADA List of Prohibited Substances and Prohibited Methods, and is therefore also prohibited under the Tennis Anti-Doping Programme. Mr Pérez Esteve was therefore charged with an Anti-Doping Rule Violation under Article 2.1 of the Programme.
Mr Pérez Esteve did not have a valid TUE for the use of terbutaline, but presented evidence that he had been prescribed terbutaline to treat a medical condition. The ITF accepted that Mr Pérez Esteve did not intend to enhance his performance through the use of terbutaline. It is a player’s strict personal duty to ensure that no Prohibited Substance enters his/her body, however as terbutaline is a ‘Specified Substance’ under the 2013 Prohibited List, there is discretion as to the sanction that is applied.
The ITF therefore confirmed Mr Pérez Esteve’s commission of an Anti-Doping Rule Violation under Article 2.1 of the Tennis Anti-Doping Programme, and determined that he be given a reprimand and no period of ineligibility. The ITF also determined that Mr Pérez Esteve’s results achieved at the F35 Futures Event should be disqualified.